Page last updated: 2024-10-19
niacin and Carotid Artery Narrowing
niacin has been researched along with Carotid Artery Narrowing in 3 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
Research Excerpts
Excerpt | Relevance | Reference |
"Niacin-treated subjects compared to untreated subjects had significantly less change in mean coronary stenosis (0." | 6.78 | Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment ( Brown, BG; Isquith, D; Muñoz, L; Phan, BA; Shadzi, P; Triller, M; Zhao, XQ, 2013) |
"Niacin-treated subjects compared to untreated subjects had significantly less change in mean coronary stenosis (0." | 2.78 | Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment ( Brown, BG; Isquith, D; Muñoz, L; Phan, BA; Shadzi, P; Triller, M; Zhao, XQ, 2013) |
Research
Studies (3)
Timeframe | Studies, this research(%) | All Research% |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
Phan, BA | 2 |
Muñoz, L | 1 |
Shadzi, P | 1 |
Isquith, D | 1 |
Triller, M | 1 |
Brown, BG | 1 |
Zhao, XQ | 2 |
Chu, B | 1 |
Bray, F | 1 |
Moore, AB | 1 |
Polissar, NL | 1 |
Dodge, JT | 1 |
Lee, CD | 1 |
Hatsukami, TS | 1 |
Yuan, C | 1 |
Mack, WJ | 1 |
LaBree, L | 1 |
Liu, C | 1 |
Selzer, RH | 1 |
Hodis, HN | 1 |
Clinical Trials (2)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status |
Carotid Plaque Composition by Magnetic Resonance Imaging During Lipid Lowering Therapy[NCT00715273] | Phase 4 | 217 participants (Actual) | Interventional | 2001-05-01 | Completed |
Correlates of Angiographic Changes and Coronary Events: The Cholesterol-Lowering Atherosclerosis Study (CLAS)[NCT00005433] | | 188 participants (Actual) | Observational | 1996-04-30 | Completed |
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Annualized LRNC Volume Change in Carotid Plaque Composition, as Assessed by MRI
"The primary endpoint of this study is carotid plaque lipid composition identified by MRI. The determination of plaque lipid content for each carotid artery will be performed using the automated interactive system. These measurements will be performed from the MRI scans at four time points blinded to time sequence of MRI examinations, patient treatment, lipid levels and clinical course.~Volume Measurements: Contours were placed around the lumen, outer-wall boundaries, and plaque features of carotid artery. (Arterial wall area) = (outer-wall area) - (lumen area). Volume calculated as: area x 2 mm (slice thickness). Tissue volume/wall volume x (100%) is presented as percentage. Annualized change presented mm^3/year (for volume) and as percentage change/year." (NCT00715273)
Timeframe: Measured at Years 1, 2, and 3
Intervention | mm^3/year (Mean) |
---|
1 - Single Therapy Group | -4.6 |
2 - Double Therapy Group | -15.1 |
3 - Triple Therapy Group | -9.4 |
Annualized LRNC and Wall Volume Changes in Carotid Plaque Composition, as Assessed by MRI
"The primary endpoint of this study is carotid plaque lipid composition identified by MRI. The determination of plaque lipid content for each carotid artery will be performed using the automated interactive system. These measurements will be performed from the MRI scans at four time points blinded to time sequence of MRI examinations, patient treatment, lipid levels and clinical course.~Volume Measurements: Contours were placed around the lumen, outer-wall boundaries, and plaque features of carotid artery. (Arterial wall area) = (outer-wall area) - (lumen area). Volume calculated as: area x 2 mm (slice thickness). Tissue volume/wall volume x (100%) is presented as percentage. Annualized change presented mm^3/year (for volume) and as percentage change/year." (NCT00715273)
Timeframe: Measured at Years 1, 2, and 3
Intervention | percentage change/year (Mean) |
---|
| LRNC change | Wall Volume change |
---|
1 - Single Therapy Group | -1.6 | -0.6 |
,2 - Double Therapy Group | -3.6 | -1.4 |
,3 - Triple Therapy Group | -2.8 | -1.2 |
Composite of Cardiovascular Endpoints: Number of Participants With Cardiovascular Disease Death, Non-fatal Heart Attack, Stroke, and Worsening Ischemia Requiring Medical Interventions
Any cardiovascular events such as death from any cause, nonfatal myocardial infarction, stroke, and revascularization procedures (PCI or CABG) due to unstable ischemia will be recorded and verified. (NCT00715273)
Timeframe: Measured at Years 3, 4, and 5
Intervention | Participants (Count of Participants) |
---|
| Composite Measured at Year 3 | Composite Measured at Year 4 (cumulative) | Composite Measured at Year 5 (cumulative) |
---|
1 - Single Therapy Group | 6 | 7 | 9 |
,2 - Double Therapy Group | 6 | 11 | 11 |
,3 - Triple Therapy Group | 7 | 9 | 9 |
Trials
3 trials available for niacin and Carotid Artery Narrowing
Article | Year |
Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis TreatmentThe American journal of cardiology, 2013, Feb-01, Volume: 111, Issue:3
Topics: Blood Glucose; Carotid Stenosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary | 2013 |
Testing the hypothesis of atherosclerotic plaque lipid depletion during lipid therapy by magnetic resonance imaging: study design of Carotid Plaque Composition Study.American heart journal, 2007, Volume: 154, Issue:2
Topics: Allylamine; Atherosclerosis; Atorvastatin; Carotid Stenosis; Colesevelam Hydrochloride; Double-Blind | 2007 |
Correlations between measures of atherosclerosis change using carotid ultrasonography and coronary angiography.Atherosclerosis, 2000, Volume: 150, Issue:2
Topics: Adult; Carotid Artery, Common; Carotid Stenosis; Colestipol; Coronary Angiography; Coronary Artery D | 2000 |